Core Viewpoint - Fudan Zhangjiang (688505.SH) announced that Mr. Yang Zongmeng has implemented a share reduction plan, reducing his holdings in the company by 10.3657 million shares, which accounts for 1.00% of the company's total share capital [1] Group 1 - The share reduction took place between November 26, 2025, and January 12, 2026 [1] - The reduction was executed through centralized bidding transactions [1]

Group 1 - The major shareholder, Yang Zongmeng, held 64,009,773 shares, representing 6.18% of the total share capital before the reduction plan [2] - Yang Zongmeng planned to reduce his holdings by up to 10,365,721 shares, which is no more than 1.00% of the total share capital, due to personal funding needs [3] - The reduction was successfully completed between November 26, 2025, and January 12, 2026, with a total of 10,365,721 shares sold, matching the planned reduction [4]

Shareholder Reduction - New China Group's shareholder, New Work Group, plans to reduce its stake by no more than 3% [1] - Shuyuan Pingmin's shareholder, Alibaba Health, intends to reduce its stake by no more than 2% [1] - Zhejiang Yongqiang's shareholder, Xie Jianqiang, plans to reduce his stake by no more than 1.13% [1] - Xiangyu Medical's shareholder, Anyang Qixu, intends to reduce his stake by no more than 3% [1] - Zhangyue Technology's shareholder, Quantum Leap, plans to reduce its stake by no more than 1% [1] - Fudan Zhangjiang's shareholder, Yang Zongmeng, has reduced 10.3657 million shares [1] - Saiwei Times' shareholder, Zhongteng Investment, has reduced 12.1037 million shares [1] - Aokang International's shareholder, Xiang Jinyu, has cumulatively reduced 1.21% of the company's shares [1] - Fute Technology's shareholder, Changjiang Weilai Industrial Fund, has cumulatively reduced 1.6492% of the shares [1] - New Giant's shareholder, Suzhou Houqi, has cumulatively reduced 1.4997% of the shares [1] - Baolingbao's shareholder, De Pufutong, has cumulatively reduced 1.10689% of the shares [1] - Hongqiang's actual controller, Liu Lianjun, plans to reduce his stake by no more than 1% [1] - Yashiguangdian's shareholder, Bian Ruiqun, has cumulatively reduced 1.0695% of the shares [1] Other Financial Issues - Ruimao Tong has reported overdue debts amounting to approximately 856 million yuan [1] - *ST Dongjing is under investigation by the Securities Regulatory Commission due to independent director Fu Baoshan's suspected insider trading [1]

Core Viewpoint - Fudan Zhangjiang (01349) announced that Mr. Yang Zongmeng has implemented a share reduction plan, reducing his holdings in the company [1] Summary by Relevant Sections - Share Reduction Details - Mr. Yang Zongmeng reduced his shareholding by a total of 10,365,721 shares from November 26, 2025, to January 12, 2026, which represents 1.00% of the company's total share capital [1] - The total amount of the reduction is approximately 91.083 million yuan [1]

Core Viewpoint - Fudan Zhangjiang (01349) has announced a share reduction plan implemented by Mr. Yang Zongmeng, involving a total reduction of 10,365,721 shares, which represents 1.00% of the company's total share capital, with a total amount of approximately 91.083 million yuan [1] Group 1 - The share reduction occurred between November 26, 2025, and January 12, 2026, through centralized bidding transactions [1] - The total number of shares reduced is 10,365,721 [1] - The total amount from the share reduction is approximately 91.083 million yuan [1]

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份結果公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 中國·上海 二零二六年一月十三日 *僅供識別 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 曲亞楠女士（職工董事） 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2026-002 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 64,009,773 股，占公司总股本 的 6.18%。杨宗孟先生所持有的公司股份来源为公司首次公开发行前取得的股份， 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 1、2025 年 11 月 5 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-038）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365,721 股，拟减持比例不超过公司总股本的 1.00%。 2、公司于近日收到杨宗孟先生出具的《关于股份减持计划实施 ...

Summary of Key Points Core Viewpoint - Fudan Zhangjiang announced that shareholder Yang Zongmeng plans to reduce his stake in the company due to personal financial needs, with a specific reduction plan outlined for the upcoming years [1] Group 1: Shareholder Information - Yang Zongmeng held 64,009,773 shares before the reduction plan, representing 6.18% of the total share capital [1] - The shares held by Yang Zongmeng became fully tradable starting from June 19, 2023 [1] Group 2: Reduction Plan - Yang Zongmeng intends to reduce his holdings by up to 10,365,721 shares, which is not more than 1% of the total share capital, starting from November 5, 2025 [1] - The planned reduction period is from November 26, 2025, to January 12, 2026, during which he aims to sell the aforementioned shares [1] Group 3: Financial Details - The reduction price is expected to range between 8.64 and 9.22 yuan per share, with a total amount of approximately 91.083 million yuan from the sale [1] - After the reduction, Yang Zongmeng's shareholding will decrease to 53,644,052 shares, representing 5.18% of the total share capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購招商銀行結構性存款產品 認購結構性存款產品 近日，本公司與招商銀行訂立招商銀行結構性存款產品協議 I，本公司之全資附屬公司泰州復旦 張江與招商銀行訂立招商銀行結構性存款產品協議 II，據此，本集團同意以日常營運產生的自有 閑置資金向招商銀行認購總金額為人民幣 1.10 億元的結構性存款產品。 上市規則的涵義 根據上市規則第 14.22 條，招商銀行結構性存款產品協議項下的交易需合併計算。在訂立招商銀 行結構性存款產品協議時，就招商銀行結構性存款產品協議項下產品的總認購金額合計而言，一 項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則第 14章，该等交易構成本公司之須予披露的交易，須遵守上市規則第14章有關申報及公告之規定， 惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與招商銀行訂立招商銀行結構性存款產品協議 I，本公司之全資附屬公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 上市規則的涵義 在訂立平安銀行結構性存款產品協議時，就平安銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議，同意以日常營運產生的自有閑置資金 向平安銀行認購金額為人民幣 2.70 億元的結構性存款產品。 - 1 - 平安銀行結構性存款產品協議 須予披露的交易 認購平安銀行結構性存款產品 認購結構性存款產品 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議，同意以日常營運產生的自有閑置資 金向平安銀行認購金額為人民幣 2.70 億元的結構性存款產品。 本公司與平安銀行訂立之結構性存款產品協議的主要條款載列如下： 實際年 ...